A Phase 2 Open-Label Single-Arm Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 09 Jan 2020
Price : $35 *
At a glance
- Drugs Loncastuximab tesirine (Primary)
- Indications B-cell lymphoma; Diffuse large B cell lymphoma
- Focus Registrational; Therapeutic Use
- Sponsors ADC Therapeutics
- 09 Jan 2020 According to an ADC Therapeutics Media Release, company plan to present final data from this trial at a future scientific meeting.
- 09 Jan 2020 Results presented in an ADC Therapeutics Media Release.
- 09 Dec 2019 Interim Results presented in an ADC Therapeutics Media Release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History